AbbVie Submits Supplemental New Drug Application to U.S. FDA to Support New Indication of LINZESS® (linaclotide) for Functional Constipation in Children and Adolescents 6 to 17 Years of Age

/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that it has submitted a supplemental New Drug Application (sNDA) for linaclotide (LINZESS®) to the U.S....

Related Keywords

United States ,Rome ,Lazio ,Italy ,Clin Gastroenterol ,Celine Goldberger ,Instagram ,Jerome Foundation ,Linkedin ,Drug Administration ,Ironwood Pharmaceuticals ,Exchange Commission ,Youtube ,Allergan ,Facebook ,Abbvie Inc ,New Drug Application ,Common Adverse Reactions ,Allergan Aesthetics ,Private Securities Litigation Reform Act ,Quarterly Reports ,Childhood Functional Gastrointestinal Disorders ,Functional Gastrointestinal Disorders ,Pract Res Clin ,Abbvie ,